Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 32,705 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 32,705 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $5.50, for a total value of $179,877.50. Following the sale, the insider directly owned 708,587 shares of the company’s stock, valued at approximately $3,897,228.50. This represents a 4.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The stock was sold at an average price of $6.27, for a total value of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The stock was sold at an average price of $6.09, for a total value of $19,457.55.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total transaction of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total transaction of $18,790.44.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The shares were sold at an average price of $5.87, for a total transaction of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total transaction of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total transaction of $76,081.95.
• On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The shares were sold at an average price of $6.03, for a total transaction of $24,952.14.
• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total value of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $42,830.37.

Clene Trading Down 18.9%

NASDAQ:CLNN opened at $5.18 on Tuesday. The business’s fifty day moving average price is $7.54 and its 200 day moving average price is $6.45. The firm has a market capitalization of $53.51 million, a price-to-earnings ratio of -1.53 and a beta of 0.87. Clene Inc. has a 1-year low of $2.28 and a 1-year high of $13.50.

Clene (NASDAQ:CLNN) last released its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. Equities analysts forecast that Clene Inc. will post -5.19 earnings per share for the current year.

Institutional Trading of Clene

Institutional investors and hedge funds have recently made changes to their positions in the stock. Scoggin Management LP boosted its stake in shares of Clene by 75.1% during the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after acquiring an additional 107,250 shares in the last quarter. Lunt Capital Management Inc. boosted its position in Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after purchasing an additional 1,250 shares during the period. Jane Street Group LLC acquired a new position in Clene during the second quarter valued at approximately $47,000. Finally, Jones Financial Companies Lllp bought a new position in shares of Clene in the third quarter valued at approximately $29,000. Institutional investors and hedge funds own 23.28% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Benchmark restated a “buy” rating on shares of Clene in a report on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research note on Friday. UBS Group reaffirmed a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Finally, D. Boral Capital reiterated a “buy” rating and set a $23.00 price target on shares of Clene in a report on Friday. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Clene presently has an average rating of “Moderate Buy” and an average price target of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).